Summary
Christopher Butch is an associate professor at Nanjing University who leads a translational bioengineering group combining computational design, kinetic optimization, and hands-on experiments to advance therapeutics and diagnostics toward clinical impact. With 11 years of experience spanning a PhD in Chemical and Biomolecular Engineering and postdoctoral work at Emory and Tokyo Tech, he focuses on the cancer–immune interface using structure-based modeling and machine learning to overcome immune evasion and improve checkpoint outcomes. His lab has advanced real-world candidates—such as NY-07, a folate receptor α–selective imaging agent now in Phase II, and ACT-vac, a rapid-turnaround personalized vaccine platform—illustrating a rare end-to-end pipeline from in silico design to clinical translation. Based in Hong Kong, he blends fundamental physical chemistry and systems-level engineering to optimize molecules, delivery, and treatment timing, often shrinking production timelines from weeks to days.
11 years of coding experience
1 year of employment as a software developer
Bachelor of Science (B.S.), Chemical and Biomolecular Engineering, Bachelor of Science (B.S.), Chemical and Biomolecular Engineering at University of South Carolina-Columbia
Doctor of Philosophy (PhD), Chemical and Biomolecular Engineering, Doctor of Philosophy (PhD), Chemical and Biomolecular Engineering at Georgia Institute of Technology